1. Home
  2. VERU vs WYY Comparison

VERU vs WYY Comparison

Compare VERU & WYY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veru Inc.

VERU

Veru Inc.

SELL

Current Price

$3.06

Market Cap

48.2M

Sector

Health Care

ML Signal

SELL

Logo WidePoint Corporation

WYY

WidePoint Corporation

HOLD

Current Price

$15.45

Market Cap

107.8M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERU
WYY
Founded
1971
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
48.2M
107.8M
IPO Year
1996
2005

Fundamental Metrics

Financial Performance
Metric
VERU
WYY
Price
$3.06
$15.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$22.50
$8.67
AVG Volume (30 Days)
5.5M
150.3K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.01
Revenue
$16,296,958.00
$150,545,364.00
Revenue This Year
N/A
$14.41
Revenue Next Year
N/A
$11.41
P/E Ratio
N/A
$1,371.00
Revenue Growth
N/A
5.59
52 Week Low
$0.36
$2.80
52 Week High
$7.33
$13.89

Technical Indicators

Market Signals
Indicator
VERU
WYY
Relative Strength Index (RSI) 55.43 81.09
Support Level $2.15 $4.76
Resistance Level $3.68 N/A
Average True Range (ATR) 0.67 1.17
MACD -0.02 0.20
Stochastic Oscillator 18.01 99.22

Price Performance

Historical Comparison
VERU
WYY

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

Share on Social Networks: